TPG Pace Beneficial Finance Corp. (TPGY) to Liquidate Trust
by Marlena Haddad on 2022-09-23 at 5:15pm

TPG Pace Beneficial Finance  (NYSE:TPGY) announced in an 8-K this afternoon that it intends to liquidate its trust after being unable to complete a business combination.

The SPAC will instead redeem all of its outstanding Class A ordinary shares, effective as of October 11, 2022, and expects the last trading day for its shares to be on October 7.

The balance of TPGY’s trust account stands at $350,552,912, including the $350,000,000 in funds deposited into the account at the time of the IPO and $552,912 in interest and dividend income. Net of taxes and up to $100,000 of dissolution expenses, TPG Pace Beneficial Finance currently expects the per-share redemption price to be approximately $10.01 and will be paid on October 11.

TPG’s liquidation comes several months after it terminated its initial business combination with EVBox Group, a global provider of EV charging technologies, in December 2021. Although the termination of the $1 billion deal was mutual, the business still had to pay a fee of $17,014,631 to TPG as a reimbursement of certain transaction expenses. The reimbursement was made on January 18, 2022, and TPG has used approximately $12.6 million of that payment to fund previously incurred expenses. It expects to continue to draw from that money to pay current payables, accrued expenses, and future expenses in connection to the winding up of the SPAC’s business.

Additionally, in a letter to Shareholders, TPGY also noted how challenging market conditions have become in recent months. Karl Peterson, the Non-Executive Chairman wrote:

“…market conditions continued to deteriorate over the course of 2022 making it increasingly difficult to bridge the demands of sellers and new investors, with the new issue discounts required to successfully list a company continuing to rise. As a result, the high-quality targets we were seeking were increasingly delaying their listing timelines, pursuing alternative capital raising strategies, or both. Against this backdrop, we were unable to find a suitable transaction that was compelling for investors and met our high standards.”

TPG Pace Beneficial, which originally announced its $350 million IPO in October 2020, had 24 months to complete a business combination. The SPAC was led by Non-Executive Chairman Karl Peterson, President Michael MacDougall, CFO Martin Davidson, and Secretary Eduardo Tamraz.

 

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved